KCNN4

PRESS RELEASE November 3, 2022 SAN903 has finalized preclinical development and fulfilled other requirements for clinical developmentPotential first-in-class compound offers a new treatment paradigm for inflammatory and fibrotic diseases Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that SAN903 is ready to start the regulatory process for entering Phase 1 clinical trials either by Saniona alone or together with a partner following successful completion of preclinical development. “Preclinical data for SAN903 are very compelling and we believe it has potential to become first-line treatment in patients suffering from inflammatory bowel disease, IBD, where it could be the first maintenance drug with independent actions on both acute inflammation and chronic fibrotic complications. Other potential indications include fibrotic disorders such as chronic kidney disease, CKD, and the fatal lung disease idiopathic pulmonary fibrosis, IPF. There is a significant unmet medical need and commercial opportunities in inflammatory bowel disease and rare fibrotic disorders,” said Thomas Feldthus, Chief Executive Officer of Saniona. SAN903 is a novel, potential first-in-class medicine based on inhibition of the calcium-activated potassium ion channel, KCa3.1. This ion channel is found on several types of immune cells, where it participates in the control of the cellular pathways that maintain pathogenic activation and inflammation in chronic diseases. The KCa3.1 channel is also expressed on fibroblasts, especially on myofibroblasts, where it supports the overproduction of connective tissue that can lead to fibrosis. Prevention of fibrotic complications is an aspect of the disease, which is poorly treated by current standard-of-care IBD medicines, and progressed fibrosis often requires surgical intervention to resolve potentially life-threatening gut obstructions. SAN903 dampens inflammation and fibrosis by preventing cell division and cell migration of activated immune cells and fibroblast and by impeding cytokine release and collagen secretion of the respective cell types. Palle Christophersen, EVP Research, commented: I am incredibly happy that SAN903 – which is the result of a long and challenging drug discovery phase – has now successfully completed the preclinical development package and is ready for entering the clinical stages. Inflammatory bowel disease is a complex disease with a rather low initial responder rate and poorly controlled disease progression. Due to its new mode-of-action, I anticipate that the entry indication for SAN903 can be newly diagnosed, mild-to-moderate colitis patients that are failing first-line treatment with standard-of-care medicine. Due to the actions on both inflammatory and fibrotic processes, I hope that SAN903 can become the first maintenance drug, which effectively prevents development of intestinal fibrosis in patients suffering from inflammatory bowel disease. For more information, please contact Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com This information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on 3 November 2022. About Saniona Saniona is a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels. The company’s most advanced product candidate, Tesomet™, has been progressed to mid-stage clinical trials for rare eating disorders. Through its ion channel expertise, Saniona is advancing two product candidates, SAN711and SAN903. SAN711 has successfully completed a Phase 1 clinical trial for the treatment of neuropathic pain conditions. SAN903 is ready for Phase 1 clinical studies for the treatment of inflammatory and fibrotic disorders. The company has research and development partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cephagenix ApS. Saniona is based in Copenhagen, Denmark, and listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at http://www.saniona.com. About inflammatory bowel diseases It is estimated that 2.5 million patients are diagnosed with IBD (1 million colitis and 1.5 million Crohn’s patients) in the seven major markets (USA, Japan; 5 major EU countries). The incidences are increasing, especially in newly industrialized countries, presumably due to changes in lifestyle. Currently used anti-IBD drugs are anti-inflammatory (5-ASA´s, steroids, JAK inhibitors), generally immune dampening (azathioprine, 6-mercaptopurine), or biological single cytokine/integrin neutralizing agents (e.g. infliximab, ustekinomab, vedolizumab). Despite these options and carefully optimized clinical procedures, patients still face rounds of gut-shortening surgeries (many Crohn’s patients experience at least one surgery in their lifetime), and colitis patients may develop proctitis after colectomy. Suboptimal medical disease control with respect to maintaining long-term remission, to fight flare ups, and especially avoiding development of irreversible structural changes due to irresolvable gut fibrosis, represents a serious unmet need for IBD patients. Attachment 20221103 Saniona SAN903 (UK)

BOSTON and SEONGNAM, South Korea, Sept. 1, 2022 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, presented the non-clinical study results of 'BBT-301', a novel, small molecular inhibitor of KCa 3.1, and 'BBT-209', an endogenous GPCR19 agonist, both being developed as novel IPF treatments, at the 6th Annual IPF Summit (August 29 - September 1, 2022), in Boston, MA. During the poster presentation titled "BBT-301: a potent KCa3.1 modulator in development to treat idiopathic pulmonary fibrosis", the company highlighted the potent anti-fibrotic efficacy of BBT-301, observed through cell-based biochemistry assays and animal model studies. BBT-301 inhibits KCa 3.1, a calcium-activated potassium channel at an IC50 (inhibitory concentration 50%) of 6nM, which suggests a competitive channel inhibitory efficacy in the same class of candidates. BBT-301 also improved pulmonary function, and attenuated Ashcroft and collagen deposition in bleomycin (BLM)-induced animal model. According to the in-vivo data exhibited at the poster presentation, BBT-301 inhibited the expression of collagen in a dose-dependent manner. In terms of forced vital capacity (FVC) and pressure-volume curve, BBT-301 has also shown comparable potency in lung function recovery compared to the current standard of care (SoC). In addition to BBT-301, the company unveiled non-clinical data of BBT-209, under the title of "BBT-209: endogenous GPCR19 agonist attenuates animal model of idiopathic pulmonary fibrosis". According to the poster presentation, BBT-209 has exhibited competitive inhibitory effects against cytokine expressions such as IL-1β and TNF-α, with EC50 (effective concentration of 50%) of 0.031 and 0.36 μM each. Through the cell-based biochemistry assay and the BLM mouse model, BBT-209 also exhibited a strong anti-inflammatory effect reaching over 80%, and inhibitory efficacy of α-SMA (α-smooth muscle actin) expression, which is suggestive of combination therapies with the current standard of care and novel IPF treatments with strong anti-fibrotic drugs such as BBT-877, which is being developed as a potent best-in-class autotaxin inhibitor. "We are excited to present the non-clinical data of BBT-301 and BBT-209, our new assets being developed for the treatment of IPF," said James Lee, founder and CEO of Bridge Biotherapeutics. "In addition to our commitment to develop novel treatment options with therapeutic benefits, we will continue to enhance our pipeline to address the significant unmet needs in IPF, a serious disease caused by various factors." Posters presented at the conference is available at: https://bit.ly/3CPAxmS. About Bridge Biotherapeutics, Inc. Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs including ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations. SOURCE Bridge Biotherapeutics, Inc.

PRESS RELEASE June 24, 2022 Saniona (OMX: SANION), a clinical stage biopharmaceutical company, today announced that professor Helle Prætorius, Univ. of Aarhus, Denmark, made a presentation at the ECM conference, 2022, which shows that SAN903 protects against fibrosis in a chronic kindney dease model. Chronic kidney disease (CKD) is a devastating, progressive deterioration of renal function that significantly impacts the quality of life for the individual and represents a substantial cost for the society. Regardless of the cause of CKD, renal fibrosis is a major component of the disease and is the best predictor of progression to CKD-associated renal failure. Saniona’s collaborator professor Helle Prætorius, MD-PhD, Univ. of Århus, Denmark demonstrated in her presentation that Saniona’s KCa3.1 inhibitor SAN903 dampened renal fibrosis in a mouse model of CKD. When SAN903 was administrated daily during unilateral urinary obstruction the total fibrotic area was reduced by up to 43% (p>0.0001). SAN903 was well tolerated at all doses. Primary investigator, Helle Prætorius said: “SAN903 and KCa3.1 inhibitors in general present as potential therapeutic candidates for the prevention of fibrosis progression in chronic kidney disease and other fibrotic disorders”. Palle Christophersen, EVP Research of Saniona said: “We have previously demonstrated in multiple preclinical models that SAN903 dampens inflammation and fibrosis. The new data from the chronic kidney disease model further strengthen our confidence in SAN903 as a potential treatment for serious inflammatory and fibrotic disorders, which currently are without effective treatment options.” SAN903 is a novel, potential first-in-class medicine based on inhibition of the calcium-activated potassium ion channel, KCa3.1. This ion channel is found in immune cells and fibroblasts where it participates in the control of cell proliferation and migration as well as cytokine and collagen production. Previous studies have indicated that KCa3.1 inhibition may reduce inflammation and fibrosis in various diseases. Saniona expects to complete regulatory preclinical development mid 2022 and to initiate Phase 1 clinical trials end 2022 or early 2023. For more information, please contact Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com This information was submitted for publication, through the agency of the contact person set out above, at 08.00 CEST on 24 June 2022. About Saniona Saniona is a clinical-stage biopharmaceutical company with a mission to leverage its ion channel targeting expertise to discover, develop and deliver innovative rare disease treatments. The company’s most advanced product candidate, Tesomet™, has been progressed into mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. These clinical trials are voluntarily paused due to funding limitations and Saniona is actively exploring partnering opportunities. Saniona has developed a proprietary ion channel drug discovery engine anchored by IONBASE™, a database of more than 130,000 compounds, of which more than 20,000 are Saniona’s proprietary ion channel modulators. Through its ion channel expertise, Saniona is advancing two wholly-owned ion channel modulators, SAN711, SAN903. SAN711 is in a Phase 1 clinical trial and is positioned for the treatment of neuropathic pain conditions; SAN903 is in preclinical development for rare inflammatory, fibrotic and hematological disorders. Saniona is based in the Copenhagen area, Denmark, and is listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at http://www.saniona.com. Attachment 20220624 Saniona SAN903 kidney fibrosis ECM (UK)